Drugs that contain Inclisiran Sodium
1. Drug name - LEQVIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(6 months ago) | |
| US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(5 months ago) | |
| US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(4 months from now) | |
| US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(1 year, 1 month from now) | |
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(1 year, 3 months from now) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 5 months from now) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 5 months from now) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 5 months from now) | |
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(4 years from now) | |
| US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
| US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(6 years from now) | |
| US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(6 years from now) | |
| US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(6 years from now) | |
| US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(7 years from now) | |
| US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(11 years from now) | |
| CN1312856A | NOVARTIS | Enzymatic Nucleic Acid Treatment Of Diseases Or Conditions Associated With Hepatitis C Virus Infection |
Nov, 2004
(17 years ago) | |
| CN1630724A | NOVARTIS | Method For Inhibiting Expression Of Target Gene |
Jan, 2007
(15 years ago) | |
| CN1608131A | NOVARTIS | Medicine For Treating Pancreatic Cancer |
Jan, 2009
(13 years ago) | |
| CN1608133A | NOVARTIS | Double-Stranded Ribonucleic Acid For Treating Positive (+) Chain Rna Virus Infection Of Suffers |
Sep, 2009
(13 years ago) | |
| CN1604783A | NOVARTIS | The Medicine For Treating Fibrosis Disease By Rna Interference |
Dec, 2009
(12 years ago) | |
| CN1650010A | NOVARTIS | Method For Inhibiting Expression Of Target Gene And Medicine For Treating Tumour Disease |
Jan, 2010
(12 years ago) | |
| CN101605892A | NOVARTIS | Rna Interference Mediated Inhibition Of Hepatitis C Virus |
Aug, 2012
(10 years ago) | |
| CN102124107A | NOVARTIS | Rna Interference Mediated Inhibition Of Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Gene Expression Using Short Interfering Nucleic Acid (Sina) |
May, 2013
(9 years ago) | |
| CN101426912A | NOVARTIS | Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference |
Jun, 2013
(9 years ago) | |
| CN102006890A | NOVARTIS | Targeting Lipid |
Oct, 2015
(6 years ago) | |
| CN101484588A | NOVARTIS | Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene |
May, 2019
(3 years ago) | |
| CN101484588B | NOVARTIS | Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene |
May, 2019
(3 years ago) | |
| CN1835897A | NOVARTIS | Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank |
Aug, 2024
(1 year, 11 months from now) | |
| CN1835897B | NOVARTIS | Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank |
Aug, 2024
(1 year, 11 months from now) | |
| CN104854242A | NOVARTIS | Pcsk9 Irna Composition And Using Method Thereof |
Dec, 2033
(11 years from now) | |
| CN104854242B | NOVARTIS | Pcsk9 Irna Composition And Using Method Thereof |
Dec, 2033
(11 years from now) | |
| IN200300537P3 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| IN213846B | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| IN203882B | NOVARTIS | Method For Inhibiting The Expression Of A Targe Gene |
Jan, 2022
(8 months ago) | |
| IN200300572P3 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| IN200806166P4 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| IN269138B | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| IN368763B | NOVARTIS | Pcsk9 Irna Compositions And Methods Of Use Thereof |
Dec, 2033
(11 years from now) | |
| IN201503007P4 | NOVARTIS | Pcsk9 Irna Compositions And Methods Of Use Thereof |
Dec, 2033
(11 years from now) | |
| EP748382A1 | NOVARTIS | Non-Nucleotide Containing Enzymatic Nucleic Acid |
Aug, 2014
(8 years ago) | |
| EP748382B1 | NOVARTIS | Non-Nucleotide Containing Enzymatic Nucleic Acid |
Aug, 2014
(8 years ago) | |
| EP725788B1 | NOVARTIS | 2'-Amido And 2'-Peptido Modified Oligonucleotides |
Oct, 2014
(7 years ago) | |
| EP725788A1 | NOVARTIS | 2'-Amido And 2'-Peptido Modified Oligonucleotides |
Oct, 2014
(7 years ago) | |
| EP728205B1 | NOVARTIS | Reagent For Treatment Of Arthritic Conditions |
Nov, 2014
(7 years ago) | |
| EP728205A1 | NOVARTIS | Reagent For Treatment Of Arthritic Conditions |
Nov, 2014
(7 years ago) | |
| EP1408111A2 | NOVARTIS | Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor |
Oct, 2016
(5 years ago) | |
| EP1408111B1 | NOVARTIS | Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor |
Oct, 2016
(5 years ago) | |
| EP1408111A3 | NOVARTIS | Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor |
Oct, 2016
(5 years ago) | |
| EP928290B1 | NOVARTIS | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP928290A1 | NOVARTIS | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP928290A4 | NOVARTIS | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP928290B9 | NOVARTIS | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP2363479A1 | NOVARTIS | Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945B2 | NOVARTIS | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1550719B1 | NOVARTIS | Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1550719A1 | NOVARTIS | Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945B1 | NOVARTIS | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945A3 | NOVARTIS | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP2363479B1 | NOVARTIS | Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945A2 | NOVARTIS | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1798285B1 | NOVARTIS | Methods And Medicament For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1144623B1 | NOVARTIS | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1798285A1 | NOVARTIS | Methods And Medicament For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1144623B9 | NOVARTIS | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1144623A1 | NOVARTIS | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1349927B1 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease |
May, 2021
(1 year, 4 months ago) | |
| EP1349927A2 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease |
May, 2021
(1 year, 4 months ago) | |
| EP1352061B9 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| EP1352061A2 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| EP1352061B1 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| EP2213736A2 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness |
Jan, 2022
(8 months ago) | |
| EP2213736A3 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness |
Jan, 2022
(8 months ago) | |
| EP2213736B1 | NOVARTIS | Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness |
Jan, 2022
(8 months ago) | |
| EP2415486A2 | NOVARTIS | Conjugates And Compositions For Cellular Delivery |
May, 2022
(4 months ago) | |
| EP2415486A3 | NOVARTIS | Conjugates And Compositions For Cellular Delivery |
May, 2022
(4 months ago) | |
| EP2415486B1 | NOVARTIS | Conjugates And Compositions For Cellular Delivery |
May, 2022
(4 months ago) | |
| EP1423404B1 | NOVARTIS | Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1423404A2 | NOVARTIS | Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1423404A4 | NOVARTIS | Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1572128B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1423406A2 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2902406B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2278004B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2287305A1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1430157A2 | NOVARTIS | Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2287305B2 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP3354656B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1458741A2 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid |
Feb, 2023
(4 months from now) | |
| EP2287306A1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1458741B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid |
Feb, 2023
(4 months from now) | |
| EP2278004A1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1423406B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1423406B2 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2287306B2 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2902406A1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1458741A4 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid |
Feb, 2023
(4 months from now) | |
| EP1423406A4 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1430157A4 | NOVARTIS | Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1430157B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2287305B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1572128A4 | NOVARTIS | Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2287306B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP3354656A1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP1572128A2 | NOVARTIS | Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Feb, 2023
(4 months from now) | |
| EP2957568A1 | NOVARTIS | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP1560840B1 | NOVARTIS | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP1562971A2 | NOVARTIS | Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP1560840A2 | NOVARTIS | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP1562971B1 | NOVARTIS | Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP1562971A4 | NOVARTIS | Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP2957568B1 | NOVARTIS | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP1560840A4 | NOVARTIS | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 1 month from now) | |
| EP1605978A4 | NOVARTIS | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP2216407B1 | NOVARTIS | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP2216407A3 | NOVARTIS | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP1605978A2 | NOVARTIS | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP2216407A2 | NOVARTIS | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP1605978B1 | NOVARTIS | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP1615611B1 | NOVARTIS | Irna Conjugates |
Apr, 2024
(1 year, 6 months from now) | |
| EP1615611A2 | NOVARTIS | Irna Conjugates |
Apr, 2024
(1 year, 6 months from now) | |
| EP1615611A4 | NOVARTIS | Irna Conjugates |
Apr, 2024
(1 year, 6 months from now) | |
| EP1620544B1 | NOVARTIS | Modified Irna Agents |
Apr, 2024
(1 year, 6 months from now) | |
| EP1620544A2 | NOVARTIS | Modified Irna Agents |
Apr, 2024
(1 year, 6 months from now) | |
| EP1620544A4 | NOVARTIS | Modified Irna Agents |
Apr, 2024
(1 year, 6 months from now) | |
| EP1622572A2 | NOVARTIS | Conjugates And Compositions For Cellular Delivery |
Apr, 2024
(1 year, 7 months from now) | |
| EP1622572A4 | NOVARTIS | Conjugates And Compositions For Cellular Delivery |
Apr, 2024
(1 year, 7 months from now) | |
| EP1622572B1 | NOVARTIS | Conjugates And Compositions For Cellular Delivery |
Apr, 2024
(1 year, 7 months from now) | |
| EP1627061B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina) |
May, 2024
(1 year, 7 months from now) | |
| EP1627061A2 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina) |
May, 2024
(1 year, 7 months from now) | |
| EP1765074A2 | NOVARTIS | Positionally Modified Sirna Constructs |
Jun, 2024
(1 year, 8 months from now) | |
| EP1765074A4 | NOVARTIS | Positionally Modified Sirna Constructs |
Jun, 2024
(1 year, 8 months from now) | |
| EP1765074B1 | NOVARTIS | Positionally Modified Sirna Constructs |
Jun, 2024
(1 year, 8 months from now) | |
| EP1667944B1 | NOVARTIS | Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour |
Aug, 2024
(1 year, 11 months from now) | |
| EP1667944A1 | NOVARTIS | Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour |
Aug, 2024
(1 year, 11 months from now) | |
| EP1664299A1 | NOVARTIS | Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Sep, 2024
(1 year, 11 months from now) | |
| EP1664299B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina) |
Sep, 2024
(1 year, 11 months from now) | |
| EP1677822B1 | NOVARTIS | 4'-Thionucleosides And Oligomeric Compounds |
Sep, 2024
(1 year, 11 months from now) | |
| EP1677822A2 | NOVARTIS | 4'-Thionucleosides And Oligomeric Compounds |
Sep, 2024
(1 year, 11 months from now) | |
| EP1677822A4 | NOVARTIS | 4'-Thionucleosides And Oligomeric Compounds |
Sep, 2024
(1 year, 11 months from now) | |
| EP1713915A2 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina) |
Feb, 2025
(2 years from now) | |
| EP1713915B1 | NOVARTIS | Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina) |
Feb, 2025
(2 years from now) | |
| EP1799270B1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
Sep, 2025
(2 years from now) | |
| EP1799270A2 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
Sep, 2025
(2 years from now) | |
| EP1799270A4 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
Sep, 2025
(2 years from now) | |
| EP1931781B1 | NOVARTIS | Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference |
Aug, 2026
(3 years from now) | |
| EP1931781A2 | NOVARTIS | Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference |
Aug, 2026
(3 years from now) | |
| EP3578656B1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2584047B1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2584048B1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2584047A1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP3249052A1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2194128A1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP3578656A1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2584048A1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2194128B1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2835429A1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP3249052B1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP2835429B1 | NOVARTIS | Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene |
May, 2027
(4 years from now) | |
| EP3156077B1 | NOVARTIS | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP2231195A2 | NOVARTIS | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP2231194B1 | NOVARTIS | Folate-Irna Conjugates |
Dec, 2028
(6 years from now) | |
| EP3156077A1 | NOVARTIS | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP2231194A2 | NOVARTIS | Folate-Irna Conjugates |
Dec, 2028
(6 years from now) | |
| EP2231195B1 | NOVARTIS | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP2929031B9 | NOVARTIS | Pcsk9 Irna Compositions And Methods Of Use Thereof |
Dec, 2033
(11 years from now) | |
| EP2929031A1 | NOVARTIS | Pcsk9 Irna Compositions And Methods Of Use Thereof |
Dec, 2033
(11 years from now) | |
| EP2929031B1 | NOVARTIS | Pcsk9 Irna Compositions And Methods Of Use Thereof |
Dec, 2033
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(1 year, 1 month from now) | |
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(5 years from now) | |
| US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(13 years from now) | |
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.